Top news of the week: 21.07.2021.
Startups
A tale of 2 (bio) cities: Moderna tops $100B valuation, matching GlaxoSmithKline
Moderna's market cap hit $100 billion on Wednesday, briefly matching Big Pharma GlaxoSmithKline, as the pandemic cements the once controversial biotech into a major behemoth.
Pivot Bio Nears $2 Billion Valuation As It Raises Whopping $430 Million To Replace Synthetic Fertilizers On Corn And Wheat
Pivot Bio broke the code on using microbes to get crops to self-fertilize, allowing farmers to replace their synthetic chemical fertilizers. It's now worth nearly $2 billion.
Panakès moves into biotech investing with new €150M fund
Panakès has raised a €150 million ($177 million) fund that will extend its focus beyond medtech and into biotech. The VC shop will mainly use the money to invest in the series A rounds of ...
How to Protect Your Intellectual Property as a Biotech Startup
Biotech companies need to start developing long-term intellectual property strategies almost as early as they are devising their ideas.
COVID-19 drug developer Adagio plans IPO to cap fast rise
The offering is the latest step in the rapid emergence of Adagio, which raised $465 million and brought a drug to pivotal testing in less than a year.
GSK sells off part of its U.K. R&D site to rake in $554M and boost biotech ops
GlaxoSmithKline is planning to sell more than one-third of its 92-acre R&D site in Stevenage, U.K. The proposed sale, which comes amid criticism of GSK’s historically low R&D investment, is ...
“Mind the Gap” in Deal-Making
When it comes to deal valuation for early technologies, how can both sides find common ground?
Investing at the Nexus of Biology & Technology: Jenny Rooke on The Long Run
Today’s guest on The Long Run is Jenny Rooke. Jenny is the founder and managing partner of San Francisco-based Genoa Ventures. I’ve been wanting to invite Jenny on the podcast for a while. ...